Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip

Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip

The current management of osteoarthritis is based on non-pharmacological and pharmacological means which include intra-articular injections.

The recommendations on the management of hip osteoarthritis stipulate that intra-articular injections of corticosteroid may be considered in patients with an exacerbation not responding to oral treatments. Several recent studies show the effectiveness of intra-articular corticosteroids compared with anesthetics. The intra-articular injection of viscosupplementation alone has never been validated in this indication since controlled studies did not show efficacy over placebo. At present, viscosupplementation is considered an anti-osteoarthritic symptomatic slow-acting and its interest is not yet established in hip osteoarthritis.

Show the superiority of intra-articular injection of viscosupplementation in combination with corticosteroid compared to intra-articular injection of corticosteroid alone in the treatment of hip osteoarthritis.

Inclusion Criteria:

• patients with hip osteoarthrosis (stage II et III according Kellgren et Lawrence)
• walking alone patients
• patient consenting to participate to the study
• patient enrolled in the national healthcare insurance program
• patient older than 18 years

Exclusion Criteria:

• Patients with hip osteoarthrosis (stage I et IV according Kellgren et Lawrence)
• patients with rapidly destructive hip osteoarthritis
• patients with inflammatory rheumatism
• patients with microcrystalline arthritis
• patients with hip osteonecrosis
• patients who received corticosteroids during the previous three months
• patients who received a intra articular injection of viscosupplementation during the previous six months
• patient with haemostatic disorder
• patient with consumption of painkillers tier 3